Clinical trials for lung cancer

130 currently recruiting clinical trials
Lung cancer

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
Hoffmann-La Roche
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
AstraZeneca
Phase 3 Lung cancer
#NCT06635824
NSCLC (Non-Small Cell Lung Cancer) Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 Immunotherapy Chemotherapy
ALK BRAF EGFR KRAS G12C KRAS non G12C MET RET ROS-1 Systemic Treatment-Naive Car-T
Hôpital Privé du Confluent - Vivalto Santé (Nantes), Hôpital Ambroise-Paré AP-HP (Boulogne-Billancourt), CHU de Rennes - Hôpital Pontchaillou (Rennes), Centre Hospitalier Universitaire Angers (Angers )
Genmab
Phase 3 Lung cancer
#NCT06312137
NSCLC (Non-Small Cell Lung Cancer) Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive
ALK
Clinique Teissier - Valenciennes (Valenciennes), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Hôpital Tenon AP-HP (Paris ), Hôpital Larrey (Toulouse ), Hôpital Louis Pradel (Bron ) (and 4 more...)
Merck Sharp & Dohme LLC
Phase 3 Lung cancer
#NCT06345729
NSCLC (Non-Small Cell Lung Cancer) Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive
Immunotherapy
Hôpital Ambroise-Paré AP-HP (Boulogne-Billancourt), Centre hospitalier universitaire François Mitterrand (Dijon), Clinique Teissier - Valenciennes (Valenciennes), Centre Jean Perrin (Clermont Ferrand )
Merck Sharp & Dohme LLC
Phase 3 Lung cancer
#NCT06417814
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR Targeted therapy
Chemotherapy Systemic Treatment-Naive Immunotherapy Chemotherapy
Centre de Cancérologie du Grand Montpellier (Montpellier), Institut Sainte Catherine (Avignon), Hôpital d'Instruction des Armées Sainte-Anne (Toulon), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers )
AstraZeneca